Taiwan Liposome Sees Generic Of J&J Cancer Drug In Europe Next Year
This article was originally published in PharmAsia News
Taiwan Liposome said it expects its Doxisome (liposomal) generic of a treatment for breast and ovarian cancer to be on Europe's $200 million market within the next nine months and then the larger U.S. market.
You may also be interested in...
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.